Dr. Greg Katz

Dr. Steve Nissen from Cleveland Clinic, a leading figure in lipoprotein(a) research, joins Dr. Greg Katz from NYU to delve into crucial insights about this underappreciated lipid layer. They discuss why Lp(a) is essential for evaluating cardiovascular risk and who should be tested. Listeners will learn about interpreting results, managing elevated levels, and the potential roles of aspirin and PCSK9 inhibitors. The episode highlights the evolving strategies in understanding and treating Lp(a), offering a fresh perspective on patient care.

Dr. Greg Katz, a cardiologist from NYU, and Dr. Seth Baum, a preventive cardiologist, delve into the hazards of severe hypertriglyceridemia. They discuss how quickly triglyceride levels can rise and the associated risks of pancreatitis. The duo emphasizes the importance of lifestyle changes, such as diet and exercise, in managing triglyceride levels. Medications like statins and prescription omega-3s are highlighted for reducing high levels. They also touch on genetic factors and the urgency of treatment when triglycerides exceed 500 mg/dL.

Greg Katz MD, cardiologist and prevention expert at NYU focused on advanced lipidology and long-term risk reduction. He talks about when ApoB and Lp(a) change management. He explains how coronary calcium and CTA act as tiebreakers. He explores spotting early cardiometabolic risk and the role of wearables and CGMs.